The study, led by researchers at the Centenary Institute, has identified the drug currently used to treat cancer patients as the potential cause of major cure for stroke in young people.
Cerebral limb malformation (CCM) occurs when abnormal and dilatation of thin wall vessels form the brain; change the blood flow. This condition affects as many as 1 in 200 people and can cause bleeding, epilepsy and stroke.
For most patients with CCM, there is no known genetic deviation and they only become aware of their condition if they have MRI in the brain associated with an unbound condition, such as a head injury. Other patients only reveal their condition after symptoms such as fits or stroke.
Currently, CCM's only treatment is an operation that is not always possible; emphasizing the urgent need for non-invasive pharmacological treatments.
A study published in a highly recognized scientific journal Science Achievements, researchers from the Centenary Institute in Sydney and several other institutions in Australia and China have identified an appropriate candidate.
Ponatinib is a medicine approved by the Food and Drug Administration (FDA) and is currently used to treat cancer patients. Using mouse models, these researchers have discovered that the medicine also inhibits the signaling pathway of the enzyme MEKK3; a process that is one of the causes of CCM.
Dr. Jazzor Peter Choi, the researcher of the sacred author and centenary institute, says that this is an important step in the effort to find a suitable treatment for this debilitating disease.
"Our next goal is to synthesize Ponatinib derivatives for specific use in CCM to maximize its efficacy and minimize any side effects," says Dr. Choi.
Senior Author and Head of the Laboratory of Signal Censorship of the Sixteen Centers of the Year Dr. Xiangjian Zheng says they are currently talking to neurosurgeons in the United States and China in the hope of setting up a clinical trial.
"CCM is a cruel disease that many patients are unaware of having experience or stroke. If successful in clinical trials, this drug could save lives," says Dr. Zheng.
For more information about the Centenary Institute, visit http: // www.
Disclaimer: AAAS and EurekAlert! are not responsible for the news release of EurekAlert! promotional bodies or use any information through the EurekAlert system.